文献速递关节外科

术者自行收肌管阻滞不劣于麻醉医师实施阻滞:一项前瞻性随机试验

Intraoperative Surgeon Administered Adductor Canal Blockade Is Not Inferior to Anesthesiologist Administered Adductor Canal Blockade: A Prospective Randomized Trial.
PubMed 文献 · J Arthroplasty · 2020-02-28

该前瞻性随机试验将初次全膝关节置换患者分为麻醉医师实施收肌管阻滞组与术者术中实施收肌管阻滞组,使用0.5%罗哌卡因15 mL。结果显示两组在术后阿片类药物消耗量、疼痛、活动度、患者满意度及短期功能结局方面无临床显著差异,术者实施收肌管阻滞不劣于麻醉医师实施。

要点

  • 术者术中实施收肌管阻滞在疼痛、阿片消耗、活动度上不劣于麻醉医师实施。
  • 两组患者满意度与短期功能结局无差异。
  • 术者实施收肌管阻滞可作为麻醉医师实施的有效替代方案。

核心结论

  • 术者实施的收肌管阻滞在疼痛、阿片类药物消耗、活动度、患者满意度或短期功能结局方面不劣于麻醉医师实施的收肌管阻滞。
  • 术者实施的收肌管阻滞是麻醉医师实施收肌管阻滞的有效替代方案。

研究设计与样本

  • 前瞻性随机试验,纳入行初次全膝关节置换术的患者。
  • 患者随机分为麻醉医师实施收肌管阻滞组(第1组)与术者实施收肌管阻滞组(第2组),均使用0.5%罗哌卡因15 mL。

主要发现

  • 术后第0、1、2天两组阿片类药物当量消耗量相等。
  • 第1组在术后第0天疼痛评分统计学上更低,但未达临床显著性;术后第1、2天疼痛无差异。
  • 第1组术后第1天主动屈曲度显著增加,但术后第0天及术后6周主动屈曲度无差异。
  • 两组患者对疼痛控制的满意度及短期功能结局无差异。

临床怎么用

  • 术者可在术中自行实施收肌管阻滞作为麻醉医师实施的有效替代。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Controlling postoperative pain and reducing opioid requirements after total knee arthroplasty remain a challenge, particularly in an era stressing rapid recovery protocols and early discharge. A single-shot adductor canal blockade (ACB) has been shown to be effective in decreasing postoperative pain. The purpose of the present study is to compare the efficacy of an anesthesiologist administered ACB and a surgeon administered intraoperative ACB. METHODS: Patients undergoing primary total knee arthroplasty were prospectively randomized to receive either an anesthesiologist administered (group 1) or surgeon administered (group 2) ACB using 15 mL of ropivacaine 0.5%. Primary outcomes were pain visual analog scale, range of motion, and opioid consumption. RESULTS: Thirty-four patients were randomized to group 1 and 29 to group 2. Opioid equivalents consumed were equal on postoperative day (POD) 0, 1, and 2. Patients in group 1 had statistically less pain on POD 0, but this did not reach clinical significance and there was no difference in pain on POD 1 or 2. Patients in group 1 had significantly increased active flexion POD 1, but there was no difference in active flexion on POD 0 or 6 weeks postop. There was no difference in patient satisfaction with pain control or short-term functional outcomes. CONCLUSION: Surgeon administered ACB is not inferior to anesthesiologist administered ACB with respect to pain, opioid consumption, range of motion, patient satisfaction, or short-term functional outcomes. Surgeon administered ACB is an effective alternative to anesthesiologist administered ACB.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Greenky MR, McGrath ME, Levicoff EA, et al. Intraoperative Surgeon Administered Adductor Canal Blockade Is Not Inferior to Anesthesiologist Administered Adductor Canal Blockade: A Prospective Randomized Trial. J Arthroplasty. 2020. PMID: 32115328. doi:10.1016/j.arth.2020.02.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。